Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework

Note on the Sampling Error of the Difference Between Correlated Proportions or Percentages

McNemar, Q. (1947) · Psychometrika · doi:10.1007/bf02295996 · Cited by 4,754 · see citing works

The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>

Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104 · see citing works

HPV Screening for Cervical Cancer in Rural India

Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., Hingmire, S., Malvi, S. G., Thorat, R., Kothari, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808516 · Cited by 1,278 · see citing works

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

Ronco, G., Rossi, P. G., Carozzi, F., Confortini, M., Palma, P. D., Mistro, A. D., Ghiringhello, B., Girlando, S., Gillio‐Tos, A., Marco, L. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70360-2 · Cited by 935 · see citing works

Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer

Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897 · see citing works

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

Meijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692 · see citing works

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study

Castle, P. E., Stoler, M. H., Wright, T. C., Sharma, A., Wright, T. L., & Behrens, C. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70188-7 · Cited by 526 · see citing works

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial

Rijkaart, D., Berkhof, J. H., Rozendaal, L., van Kemenade, F. J., Bulkmans, N. W. J., Heideman, D. A. M., Kenter, G. G., Cuzick, J. M., Snijders, P. J. F., & Meijer, C. J. L. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70296-0 · Cited by 518 · see citing works

Measuring Agreement between Two Judges on the Presence or Absence of a Trait

Fleiss, J. L. (1975) · Biometrics · doi:10.2307/2529549 · Cited by 501 · see citing works

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial

Kitchener, H. C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., Gilham, C., Baysson, H., Roberts, C., Dowie, R., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70156-1 · Cited by 390 · see citing works

High-Risk Human Papillomavirus Testing in Women With ASC-US Cytology

Stoler, M. H., Wright, T. C., Sharma, A., Apple, R. J., Gutekunst, K. A., & Wright, T. L. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpz5jy6fcvnmot · Cited by 327 · see citing works

Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening

Nauclér, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Forslund, O., Hansson, B. G., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn444 · Cited by 287 · see citing works

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275 · see citing works

Are 20 human papillomavirus types causing cervical cancer?

Arbyn, M., Tommasino, M., Depuydt, C., & Dillner, J. (2014) · The Journal of Pathology · doi:10.1002/path.4424 · Cited by 264 · see citing works

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Monsonégo, J., Cox, J. T., Behrens, C. M., Sandri, M. T., Franco, E. L., Yap, P., & Huh, W. K. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.01.551 · Cited by 172 · see citing works

VALGENT: a protocol for clinical validation of human papillomavirus assays

Arbyn, M., Depuydt, C., Benoy, I., Bogers, J., Cuschieri, K., Schmitt, M., Pawlita, M., Geraets, D., Heard, I., Gheit, T., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.09.014 · Cited by 157 · see citing works

Multiple Human Papillomavirus Infections with High Viral Loads Are Associated with Cervical Lesions but Do Not Differentiate Grades of Cervical Abnormalities

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., & Pawlita, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00087-13 · Cited by 148 · see citing works

Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Poljak, M., Kocjan, B. J., Oštrbenk, A., & Seme, K. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.10.023 · Cited by 126 · see citing works

Commercially available assays for multiplex detection of alpha human papillomaviruses

Poljak, M., & Kocjan, B. J. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.104 · Cited by 122 · see citing works

Global Proficiency Study of Human Papillomavirus Genotyping

Eklund, C., Zhou, T., & Dillner, J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00918-10 · Cited by 122 · see citing works

On tests of equivalence via non-unity relative risk for matched-pair design

Tang, N., Tang, M., & Chan, I. S. F. (2003) · Statistics in Medicine · doi:10.1002/sim.1213 · Cited by 104 · see citing works

Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study

Eklund, C., Forslund, O., Wallin, K., & Dillner, J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02453-13 · Cited by 90 · see citing works

Erratum to: “Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer” [Vaccine 30S5 (2012) F88–F99]

Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G. S., Koliopoulos, G., Nauclér, P., Sankaranarayanan, R., & Peto, J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.003 · Cited by 82 · see citing works

Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening

Poljak, M., Oštrbenk, A., Seme, K., Učakar, V., Hillemanns, P., Bokal, E. V., Jančar, N., & Klavs, I. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00012-11 · Cited by 74 · see citing works

Need for expanded HPV genotyping for cervical screening

Cuzick, J. M., & Wheeler, C. M. (2016) · Papillomavirus Research · doi:10.1016/j.pvr.2016.05.004 · Cited by 73 · see citing works

Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening Program

Hesselink, A. T., Bulkmans, N. W. J., Berkhof, J. H., Lorincz, A. T., Meijer, C. J. L. M., & Snijders, P. J. F. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.02078-05 · Cited by 61 · see citing works

Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework

Cuschieri, K. S., Geraets, D. T., Moore, C., Quint, W. G. V., Duvall, E., & Arbyn, M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01366-15 · Cited by 59 · see citing works

Prevalence and viral load of 51 genital human papillomavirus types and three subtypes

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., Pawlita, M., & on behalf of the VALGENT Study Group (2012) · International Journal of Cancer · doi:10.1002/ijc.27891 · Cited by 59 · see citing works

Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions

Cuzick, J. M., Ho, L., Terry, G., Kleeman, M., Giddings, M. C., Austin, J., Cadman, L., Ashdown-Barr, L., Costa, M. J., & Szarewski, A. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.02.002 · Cited by 56 · see citing works

Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests)

Cuschieri, K., Geraets, D., Cuzick, J., Cadman, L., Moore, C., Vanden Broeck, D., Padalko, E., Quint, W., & Arbyn, M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00897-16 · Cited by 55 · see citing works

Viral Load of High-Risk Human Papillomaviruses as Reliable Clinical Predictor for the Presence of Cervical Lesions

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Pawlita, M., & Arbyn, M. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1067 · Cited by 52 · see citing works

Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control

Geraets, D. T., Cuschieri, K. S., de Koning, M. N. C., Doorn, L. J. V., Snijders, P. J. F., Meijer, C. J. L. M., Quint, W. G. V., & Arbyn, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01962-14 · Cited by 43 · see citing works

Cervical Cytology Biobanks as a Resource for Molecular Epidemiology

Arbyn, M., Andersson, K., Bergeron, C., Bogers, J.-P., von Knebel-Doebertitz, M., & Dillner, J. (2010) · Methods in molecular biology · doi:10.1007/978-1-59745-423-0_15 · Cited by 35 · see citing works

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel

Polman, N. J., Oštrbenk, A., Xu, L., Snijders, P. J. F., Meijer, C. J. L. M., Poljak, M., Heideman, D. A. M., & Arbyn, M. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01282-17 · Cited by 33 · see citing works

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework

Heard, I., Cuschieri, K. S., Geraets, D. T., Quint, W. G. V., & Arbyn, M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.05.004 · Cited by 29 · see citing works

A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes

Levi, A. W., Bernstein, J., Hui, P., Duch, K., Schofield, K., & Chhieng, D. C. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0027-oa · Cited by 25 · see citing works

HPV Testing of Biobanked Liquid-Based Cytology – a Validation Study

Larsson, G. L., Karlsson, M. G., & Helenius, G. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000191 · Cited by 7 · see citing works

Prevaccination Distribution of Human Papillomavirus Types in Italian Women with High-Risk Lesions and Cervical Neoplasia

Francesco, M. A. D., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., & Manca, N. (2010) · Intervirology · doi:10.1159/000317292 · Cited by 6 · see citing works

2020 list of human papillomavirus assays suitable for primary cervical cancer screening

Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284 · see citing works

The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions

Mitra, A., MacIntyre, D. A., Ntritsos, G., Smith, A., Tsilidis, K. K., Marchesi, J. R., Bennett, P. R., Moscicki, A., & Kyrgiou, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15856-y · Cited by 258 · see citing works

Meta‐analysis of the accuracy of p16 or p16/Ki‐67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology

Peeters, E., Wentzensen, N., Bergeron, C., & Arbyn, M. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22103 · Cited by 60 · see citing works

Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki‐67 dual‐stained cytology—Retrospective insights from ATHENA

Stoler, M. H., Baker, E., Boyle, S., Aslam, S., Ridder, R., Huh, W. K., & Wright, T. C. (2019) · International Journal of Cancer · doi:10.1002/ijc.32669 · Cited by 45 · see citing works

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.

Bonde, J., Ejegod, D. M., Cuschieri, K., Dillner, J., Heideman, D. A. M., Quint, W., Pavon Ribas, M. A., Padalko, E., Christiansen, I. K., Xu, L., et al. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.012 · Cited by 44 · see citing works

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework

Xu, L., Padalko, E. Y., Oštrbenk, A., Poljak, M., & Arbyn, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092704 · Cited by 37 · see citing works

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework

Bonde, J. H., Pedersen, H., Quint, W., Xu, L., Arbyn, M., & Ejegod, D. M. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01518-19 · Cited by 37 · see citing works

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework

Oštrbenk, A., Xu, L., Arbyn, M., & Poljak, M. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01176-18 · Cited by 34 · see citing works

A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional study

Inturrisi, F., de Sanjosé, S., Desai, K. T., Dagnall, C. L., Egemen, D., Befano, B., Rodríguez, A. C., Jerónimo, J., Zuna, R. E., Hoffman, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34698 · Cited by 33 · see citing works

Factors associated with HPV and other self-reported STI coinfections among sexually active Brazilian young adults: cross-sectional nationwide study

Kops, N. L., Bessel, M., Horvath, J. D. C., Domingues, C. M. A. S., de Souza, F. M. A., Benzaken, A. S., Pereira, G. F. M., Maranhão, A. G. K., Villa, L. L., Mello, B. P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027438 · Cited by 32 · see citing works

Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women

Johnson, L. G., Saidu, R., Mbulawa, Z. Z. A., Williamson, A., Boa, R., Tergas, A. I., Moodley, J., Persing, D. H., Campbell, S., Tsai, W., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3329 · Cited by 29 · see citing works

Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings

Oštrbenk, A., Šterbenc, A., Seme, K., & Poljak, M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01120-19 · Cited by 26 · see citing works

Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta

Campos, N. G., Scarinci, I. C., Tucker, L., Peral, S. L., Li, Y., Regan, M. C., Sy, S., Castle, P. E., & Kim, J. J. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1673 · Cited by 25 · see citing works

Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population‐based cervical cancer screening studies from China

Dun, C., Yuan, M., Zhao, X., Hu, S., Arbyn, M., & Zhao, F. (2024) · Cancer Medicine · doi:10.1002/cam4.7316 · Cited by 23 · see citing works

Validation of EUROArray HPV test using the VALGENT framework

Viti, J., Poljak, M., Oštrbenk, A., Bhatia, R., Boada, E. A., Cornall, A. M., Cuschieri, K. S., Garland, S. M., Xu, L., & Arbyn, M. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.005 · Cited by 23 · see citing works

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework

Dhillon, S. K., Oštrbenk, A., Xu, L., Poljak, M., & Arbyn, M. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00286-21 · Cited by 21 · see citing works

Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay

Benoy, I. H., Xu, L., Broeck, D. V., Poljak, M., Oštrbenk, A., Arbyn, M., & Bogers, J. (2019) · Journal of Clinical Virology · doi:10.1016/j.jcv.2019.09.008 · Cited by 21 · see citing works

Persistence and clearance of high‐risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study

Luckett, R. L., Painter, H., Hacker, M. R., Simon, B., Seiphetlheng, A., Erlinger, A., Eakin, C. M., Moyo, S. M., Kyokunda, L., Esselen, K. M., et al. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16758 · Cited by 18 · see citing works

Human Papillomavirus Transmission and Persistence in Pregnant Women and Neonates

Khayargoli, P., Niyibizi, J., Mayrand, M., Audibert, F., Monnier, P., Brassard, P., Laporte, L., Lacaille, J., Zahreddine, M., Bédard, M., et al. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.1283 · Cited by 17 · see citing works

High p16INK4a immunoexpression is not HPV dependent in oral leukoplakia

Tomo, S., Biss, S. P., Crivelini, M. M., Oliveira, S. H. P., Biasoli, É. R., Tjioe, K. C., Bernabé, D. G., Villa, L. L., & Miyahara, G. I. (2020) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2020.104738 · Cited by 16 · see citing works

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework

Xu, L., Oštrbenk, A., Poljak, M., & Arbyn, M. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00234-20 · Cited by 16 · see citing works

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

Ejegod, D. M., Hansen, M., Christiansen, I. K., Pedersen, H., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104336 · Cited by 16 · see citing works

Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies

Xu, L., Benoy, I. H., Cuschieri, K. S., Poljak, M., Bonde, J. H., & Arbyn, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1613890 · Cited by 15 · see citing works

Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa

Hopkins, K. L., Jaffer, M., Hlongwane, K. E., Otwombe, K. N., Dietrich, J. J., Cheyip, M., Olivier, J., Doherty, T., & Gray, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255124 · Cited by 15 · see citing works

Human Papillomavirus genotype concordance between Anyplex II HPV28 and Linear array HPV genotyping test in anogenital samples

Coutlée, F., de Pokomandy, A., Burchell, A. N., El‐Zein, M., Mayrand, M., Rodrigues‐Coutlée, S., Money, D., Comète, É., McClymont, E., Rouleau, D., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27605 · Cited by 15 · see citing works

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

Ejegod, D. M., Lagheden, C., Bhatia, R., Pedersen, H., Boada, E. A., Sundström, K., Cortés, J., José, F. X. B., Cuschieri, K. S., Dillner, J., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06888-0 · Cited by 13 · see citing works

Recent Advances in HPV Detection: From Traditional Methods to Nanotechnology and the Application of Quantum Dots

He, Z., Zheng, X., Liu, R., Zhao, K., Mao, D., Zhang, L., Wan, R., Zhang, H., & Wang, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s524518 · Cited by 12 · see citing works

Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications

Pedersen, K., Silvestre, J. D., Sy, S., Portnoy, A., Castle, P. E., Kim, J. J., & Burger, E. A. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03192 · Cited by 11 · see citing works

Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening

Volesky, K. D., Magnan, S., Mayrand, M., Isidean, S. D., El‐Zein, M., Comète, É., Franco, E. L., & Coutlée, F. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-1082 · Cited by 8 · see citing works

Cross-hybridization between HPV genotypes in the Linear Array Genotyping Test confirmed by Next-Generation Sequencing

Artaza‐Irigaray, C., Flores-Miramontes, M. G., Olszewski, D., Vallejo‐Ruiz, V., Limón-Toledo, L. P., Sánchez-Roque, C., Mayoral-Torres, R., Jave‐Suárez, L. F., & Aguilar‐Lemarroy, A. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0808-2 · Cited by 8 · see citing works

Comparison of four assays for human papillomavirus detection in the anal canal

Poynten, I. M., Jin, F., Molano, M., Machalek, D. A., Roberts, J. M., Hillman, R. J., Cornall, A. M., Phillips, S., Templeton, D. J., Law, C. L. H., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.06.027 · Cited by 8 · see citing works

HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions

Bottari, F., Iacobone, A. D., Radice, D., Preti, E. P., Preti, M., Franchi, D., Boveri, S., Sandri, M. T., & Passerini, R. (2022) · Diagnostics · doi:10.3390/diagnostics12102359 · Cited by 7 · see citing works

Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework

Bhatia, R., Boada, E. A., Bonde, J. H., Quint, W. G. V., Christiansen, I. K., Xu, L., Ejegod, D. M., Moncur, S., Cuschieri, K. S., & Arbyn, M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114161 · Cited by 5 · see citing works

Adana İlinde İnsan Papilloma Virüs (HPV) Genotip Prevalansı ve Dağılımının Belirlenmesi: 2014-2021 Yılları Arası Hastane Temelli Bir Çalışma

Alışkan, H. E., Şanlı, Ö. Ö., Bolat, F. A., Yağınç, D. A., & Toprak, U. (2023) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20239910 · Cited by 5 · see citing works

Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study

Oliveira, C. R., Ortiz, A. M., Sheth, S. S., Shapiro, E. D., & Niccolai, L. M. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043093 · Cited by 4 · see citing works

Pitfalls of commercially available HPV tests in HPV68a detection

Jaworek, H., Kubanová, K., Koudeláková, V., Slavkovský, R., Drábek, J., & Hajdúch, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220373 · Cited by 4 · see citing works

Comparative evaluation of HPV genotyping: A study on the performance concordance between Anyplex II HPV28 detection and Linear Array genotyping tests in nationwide studies in Brazil

Bandeira, I. C., Comerlato, J., Bessel, M., Fernandes, B. V., Mota, G., Villa, L. L., de Souza, F. M. A., Pereira, G. F. M., & Wendland, E. M. (2024) · PLOS ONE · doi:10.1371/journal.pone.0305122 · Cited by 3 · see citing works

Analysis of Molecular Markers of HPV Infection Persistence: A Narrative Review

Pruski, D., Millert-Kalińska, S., Wszołek, K., Musiałowicz, V., Grabowski, J. P., Jach, R., Muallem, M. Z., Sehouli, J., & Przybylski, M. (2026) · Cancers · doi:10.3390/cancers18060981 · Cited by 3 · see citing works

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework

Bhatia, R., Boada, E. A., Bonde, J. H., Quint, W. G. V., Xu, L., Ejegod, D. M., Cuschieri, K. S., & Arbyn, M. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207864 · Cited by 3 · see citing works

Anal human papillomavirus (HPV) disagreement by Linear Array compared to SPF10 PCR-DEIA-LiPA25 system in young sexual minority men

Amboree, T. L., Kuo, J. C., Sirak, B. A., Schneider, J. A., Nyitray, A. G., Hwang, L., Chiao, E. Y., Giuliano, A. R., & Fujimoto, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32336 · Cited by 3 · see citing works

Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework

Pedersen, H., Ejegod, D. M., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.12.009 · Cited by 2 · see citing works

Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework

Ejegod, D. M., Pedersen, H., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114118 · Cited by 2 · see citing works

Há maior frequência de displasia e infecção anal pelo papilomavírus humano na doença de Crohn?

Guzela, V. R. (2022) · doi:10.11606/d.5.2022.tde-19102022-102157

Human Papillomavirus Genotype Richness and the Biodiversity of Squamous and Glandular Cervical Dysplasias: A Cross-Sectional Study

Gozzini, E., Radice, D., Bottari, F., Boveri, S., Guerrieri, M. E., Preti, E. P., Spolti, N., Ghioni, M., Ferrari, F. G., & Iacobone, A. D. (2023) · Pathogens · doi:10.3390/pathogens12101234

Mapping the HPV Detection Landscape in Botswana: A Narrative Review of Diagnostic Platforms and Their Impact on Cervical Cancer Control

Tawe, L. (2026) · Health Science Reports · doi:10.1002/hsr2.72038

Validation of EUROArray HPV test using the VALGENT framework

Viti, J., Poljak, M., Oštrbenk, A., Bhatia, R., Boada, E. A., Cornall, A. M., Cuschieri, K. S., Garland, S. M., Xu, L., & Arbyn, M. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.005 · Cited by 23 · see citing works

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework

Xu, L., Padalko, E. Y., Oštrbenk, A., Poljak, M., & Arbyn, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092704 · Cited by 37 · see citing works

Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear

Monsonégo, J., Pollini, G., Evrard, M. J., Sednaoui, P., Monfort, L., Quinzat, D., Dachez, R., & Syrjänen, K. J. (2008) · International Journal of STD & AIDS · doi:10.1258/ijsa.2007.007259 · Cited by 16 · see citing works

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel

Polman, N. J., Oštrbenk, A., Xu, L., Snijders, P. J. F., Meijer, C. J. L. M., Poljak, M., Heideman, D. A. M., & Arbyn, M. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01282-17 · Cited by 33 · see citing works

CIN2+ detection by HPV DNA array genotyping assay

Pesic, A., Krings, A., Hempel, M., Preyer, R., Chatzistamatiou, Κ., Αγοραστός, Θ., Sehouli, J., & Kaufmann, A. M. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0038-1671380